Big Pharma

$740M deal ends COVID-19 vaccine feud between CureVac and BioNTech
8 August 2025   Payout and licensing deal grants US rights to COVID-19 and flu products | Agreement paves way for BioNTech’s $1.25 billion acquisition of CureVac.

Latest Features

Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler.
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
Americas
Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
Americas
The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Asia
Recent updates to China’s patent law provide guidelines on PTA calculations, definitions of delays and challenging decisions, say Audrey Cheung, Yolanda Wang and Jennifer Che of Eagle IP.
Americas
Can the FTC push through a law that has perturbed America’s life sciences industry? Unlikely, says the lawyer appointed by the world’s largest HR group opposing the move.
All features


More News

31 July 2025   The pharma manufacturer defeats an Italian hemp firm’s EU trademark bid | Claimed name could be confused for its blockbuster drug Xanax | EUIPO found strong market position and product overlap created risk of confusion.
29 July 2025   Texas pharmacy accused of mass-producing unapproved tirzepatide drugs | Lilly claimed pharmacy falsely marketed copycat versions of Mounjaro and Zepbound as safe and effective | It warned of “conducting a mass testing experiment on consumers without safety controls or informed consent”.
28 July 2025   Swiss pharma giant files patent infringement lawsuit to stop Teva’s generic Mekinist launch in US | Follows European Patent Office revocation of key patent after Teva proved lack of inventive step.
24 July 2025   Design and colour combination deemed ‘too common’ in the pharma sector for protection | Court says trademarks must be distinctive across the EU, not just individual countries.
22 July 2025   $56M awarded to AbbVie unit in Delaware patent fight over Botox treatment | US Botox sales reportedly grew to over $4.4 billion last year, while trade secrets lawsuit against rival continues.
22 July 2025   Judge said it was unjustified to allow pharma giant’s exclusivity to continue indefinitely | Loss of monopoly over $7.8bn drug set to have marked revenue impact on the company.
21 July 2025   Delhi High Court has granted an interim injunction against Zydus Lifesciences over the company’s proposed nivolumab product | BMS’s Indian patent covering the monoclonal antibody expires in May 2026.
More news